Quillivant XR (Methylphenidate HCl) Patent Expiration, LOE Window & CMS Spending

Quillivant XR (Methylphenidate HCl) by Nextwave A Sub Of Tris: FDA Orange Book LOE 2031-02-15, 1 AB generics, $98.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNextwave A Sub Of Tris
FDA Application & PathwayN202100 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-02-15
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$98.8M
2024 Medicare Part D Spend$188K
2024 Medicaid Spend$98.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel